Colchicine After Electrocardioversion for Atrial Fibrillation
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Basel, Switzerland
About this trial
The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.
Eligibility criteria
Qualifiers
Age >18 years
ECG-documented AF prior to ECV
Successful ECV with conversion of AF to sinus rhythm with persistent sinus rhythm ≥30 minutes after ECV
Ability to give written informed consent
Disqualifiers
AF persistence after cardioversion or early AF recurrence within 30 minutes after ECV
Any other rhythm than AF before cardioversion
Pulmonary vein isolation within 3 months prior to ECV or pulmonary vein isolation planned within 3 months after ECV
Known intolerance or hypersensitivity to Colchicine
Trial design
Treatments tested in this trial
- Colchicine
- Placebo
Treatment groups
416 Participants
are divided into 2 treatment groupsSponsors and collaborators
University Hospital, Basel, Switzerland
Lead sponsor
Swiss Heart Foundation
Collaborator
Fondation Machaon, Switzerland, Genf
Collaborator
Foundation for Cardiovascular Research Basel
Collaborator
Source ClinicalTrials.gov